Foster CC, et al. - Using the National Cancer Database (NCDB), researchers assessed overall survival (OS) in relation to receipt of adjuvant chemotherapy post-stereotactic body radiotherapy (SBRT) in patients with T1-T3N0M0 non-small-cell lung cancer (NSCLC). Using Kaplan-Meier methods and Cox proportional hazard models, overall 24,011 patients and 608 patients in a propensity-matched cohort were analyzed. They also performed a subset analysis for patients with tumors ≥4 cm (n = 2,323). Lower OS was observed in relation to adjuvant chemotherapy following definitive SBRT for T1-3N0M0 NSCLC, and no survival benefit of this treatment strategy was evident in patients with tumors ≥4 cm.